A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Status: Recruiting
Phase:
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT01891669 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-151

 

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Andrew Wolanski, 617-632-6623, andrew_wolanski@dfci.harvard.edu

Eligibility Criteria

Inclusion Criteria: - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available. - Performance Status of 0 or 1. - Adequate bone marrow, kidney, liver, and heart function. Exclusion Criteria: - Brain metastases requiring steroids. - Major surgery or anti-cancer therapy within 4 weeks of study treatment start. - Active bacterial, fungal or viral infection.
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms